TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy

Meryem Alagoz1,2, Owen S. Wells2 and Sherif F. El-Khamisy1,2,3,*

1Kreb’s Institute, Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield, S10 2TN, UK, 2Genome Damage and Stability Center, University of Sussex, Falmer, Brighton, BN1 9RQ, UK and 3Center of Genomics, Helmy Institute, Zewail City of Science and technology, Giza, Egypt

Received June 16, 2013; Revised November 7, 2013; Accepted November 12, 2013

ABSTRACT

Base damage and topoisomerase I (Top1)-linked DNA breaks are abundant forms of endogenous DNA breakage, contributing to hereditary ataxia and underlying the cytotoxicity of a wide range of anti-cancer agents. Despite their frequency, the overlapping mechanisms that repair these forms of DNA breakage are largely unknown. Here, we report that depletion of Tyrosyl DNA phosphodiesterase 1 (TDP1) sensitizes human cells to alkylation damage and the additional depletion of apurinic/apyrimidinic endonuclease I (APE1) confers hypersensitivity above that observed for TDP1 or APE1 depletion alone. Quantification of DNA breaks and clonogenic survival assays confirm a role for TDP1 in response to base damage, independently of APE1. The hypersensitivity to alkylation damage is partly restored by depletion of Top1, illustrating that alkylating agents can trigger cytotoxic Top1-breaks. Although inhibition of PARP activity does not sensitize TDP1-deficient cells to Top1 poisons, it confers increased sensitivity to alkylation damage, highlighting partially overlapping roles for PARP and TDP1 in response to genotoxic challenge. Finally, we demonstrate that cancer cells in which TDP1 is inherently deficient are hypersensitive to alkylation damage and that TDP1 depletion sensitizes glioblastoma-resistant cancer cells to the alkylating agent temozolomide.

INTRODUCTION

It is becoming clear that human cells use distinct but functionally overlapping pathways to protect the genome from internal and external insults. Base damage and abasic (apurinic or apyrimidinic) sites ‘AP sites’ are common forms of DNA lesions that constitute ~10^4 lesions per cell per day (1). Base damage can be triggered endogenously in living cells as a result of base oxidation or from cofactors of biochemical reactions such as S-adenosylmethionine (2). Base damage can also result from the exposure to external alkylating agents such as fuel combustion products and tobacco smoke (3,4). AP sites are generated by the spontaneous or enzymatic hydrolysis of the N-glycosylic bond linking the damaged base to the deoxyribose sugar (5). The latter is conducted by monofunctional DNA glycosylases to remove damaged bases during base excision repair (BER) (6). AP sites can be bypassed by translesion polymerases and if so processed by the short-patch or long-patch base excision repair [recently reviewed in (9,10)]. Cleavage of AP sites can also occur at the 3’-side through a δ-elimination reaction initiated by dual function DNA glycosylases/lyases, resulting in a nick with a 3’-hydroxyl and 5’-deoxyribose phosphate (5’-dRP), which are further processed by the short-patch or long-patch base excision repair [reviewed in (9,10)]. Cleavage of AP sites can also occur at the 3’-side through a β- or δ-elimination reaction initiated by dual function DNA glycosylases/lyases, resulting in a nick with a 3’-hydroxyl and 5’-deoxyribose phosphate (5’-dRP), which are further processed by the short-patch or long-patch base excision repair [reviewed in (9,10)]. Cleavage of AP sites can also occur at the 3’-side through a δ-elimination reaction initiated by dual function DNA glycosylases/lyases, resulting in a nick with a 3’-hydroxy and 5’-deoxyribose phosphate (5’-dRP), which are further processed by the short-patch or long-patch base excision repair [reviewed in (9,10)].

In addition to base damage and AP sites, another form of DNA lesion features proteins linked to DNA termini. It can arise during the normal enzymatic cycles of DNA topoisomerases where they form transient covalent

*To whom correspondence should be addressed. Tel: +44 114 2222 791; Fax: +114 2222 2850; Email: s.el-khamisy@sheffield.ac.uk

© The Author(s) 2013. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
linkage with the 3′-terminus of DNA (e.g. topoisomerase I ‘Top1’) or with the 5′-terminus (e.g. topoisomerase II ‘Top2’). These normal enzymatic cycles become abortive if the transient topoisomerase-DNA complex collides with DNA or RNA polymerases or in the presence of adjacent nicks, gaps or DNA secondary structures. Cells use specific enzymatic activities with distinct polarities to hydrolyze the covalent linkage between the stalled topoisomerase and DNA. This is typified by tyrosyl DNA phosphodiesterase 1 and 2 (TDP1 and TDP2), which remove Top1 and Top2 linked DNA breaks, respectively. The phosphodiesterase activity of TDP1 has also been implicated in processing other types of blocking 3′-lesions such as 3′-phosphoglycolates [recently reviewed in (14)]. More recently, biochemical studies using recombinant protein and cellular studies in Schizosaccharomyces pombe and chicken DT40 cells have suggested a role for TDP1 in processing AP sites and DNA phosphodiesterase 1 and 2 (TDP1 and TDP2), which remove Top1 and Top2 linked DNA breaks, respectively. The phosphodiesterase activity of TDP1 has also been implicated in processing other types of blocking 3′-lesions such as 3′-phosphoglycolates [recently reviewed in (14)].

Materials and Methods

Cell culture and transfection

Human MRC5, DLD1, T98G, U87 cells were grown in minimum essential medium (Gibco) supplemented with 10% foetal bovine serum (PAA), 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco) (18,19). RKO cells were grown in RPMI medium supplemented with 10% foetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 U/ml streptomycin. MRC5 cells were infected with Misson™ lentivirus particles (Sigma) containing shRNA targeting human TDP1 (5′-CCGGCCACGATCTCTGAAACAACTGAGTTTTGTTTCCAGAGACTGTGTTTTT3′) or with GIPZ lentivirus particles (Thermo) containing shRNA targeting human topoisomerase I (5′-CCAGGAAATGTCAAGTTTTT3′). Control ‘non target’ shRNA lentivirus particles were used as a control (Sigma). Infection was conducted for 16 h in opti-MEM (Serum free, Gibco) without antibiotic followed by addition of fresh complete medium for 24 h. Stably infected cells were maintained in 1 μg/μl puromycin (Sigma). APE1, TDP1 or Top1 transient knockdown was achieved using ON-TARGETplus Smart pool from Dharmacon. Sequences for TDP1 (CUAGACAGUUUAAGUGA, GACCA UAUCUAGAGUGAU, UCAGUUACUUGAGGC UUA, GGAGUUAAGGCAAGUAA), for Top1 (G AAAAUGGCUCUCUAGU, GAAUUCGCAUUG AAUGAUU, GCAUCAUCAUCACCCG, CGAA GAAGGUAGUAGAGUC), for APE1 (CAAAGUUC UACGCGCAUA, GAGACAAAGUUCAGAGA, C UUGCAGCCGGUAUAGA, UAACGCAUUG UAACUA) Cells maintained in suspension at 2×10⁴ per 6-cm dish were transfected with 20 μg/ml siRNA in serum-free medium (Opti-MEM) containing Metafecten (Cambio). To improve knockdown efficiency, a second round of transfection was conducted after 24 h. Knockdown efficiency was determined 48–72 h after transfection using immunoblotting. For ectopic overexpression of TDP1 and APE1 in MRC5, cells grow to 50% confluency on 60-cm dishes were transfected with 1 μg empty mammalian expression construct or 1 μg of plasmids encoding human Myc-tagged TDP1, human Flag-tagged APE1 or both, using Metafecten transfection reagent (Cambio). Expression of the fusion proteins was analyzed 24 h following transfection and survival was conducted on the same samples used to assess protein expression, as described earlier in text.

Chicken DT40 cells, were cultured a 39°C and 5% CO₂ in RPMI 1640 supplemented with 10% FCS, 1% chicken serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin with 10⁻⁵ β-mercaptoethanol. DT40 Tdp1−/− cells were described previously (20). For the generation of stable Tdp1−/− cells expressing human TDP1, 5 μg of linearized pCD2E vector containing G418 resistance cassette and 15 μg of linearized Myc-tagged hTDP1 (21) or empty vector were mixed with 5×10⁶ cells in 0.5 ml ice-cold PBS. Samples were then transferred to a Gene Pulser cuvette (Bio-Rad) with a 0.4 cm electrode gap and left for 10 min at 4°C, using the Bio-Rad Gene Pulser. Samples were then electroporated at 550 V and 25 μF and chilled on ice for 10 min. Cells were then transferred to a 10-cm dish containing 20 ml pre-warmed complete medium and left overnight at 39°C. Cells were diluted in 80 ml media supplemented with 2 mg/ml G418 for selection and aliquoted into 200 μl samples in 4×96-well plates. Cells were then left for 7 days until colonies became visible. Approximately 2 mm diameter cells were transferred to 24-well plates with 1.5 ml of pre-warmed medium and left until they reached 100% confluency (~3 days). Cells were then harvested and samples analyzed for stable clones by anti-Myc immunoblotting.

Immunoblotting

Cells were lysed in 50 mM Tris–HCl, 500 mM NaCl, 2 mM EDTA, 2 mM EGTA, 25 mM NaF, 25 mM β-glycerophosphate, 0.1 mM Naorthovanadate, 0.2% Triton X-100, 0.3% NP-40, 10 U/ml of Benzonase nuclease and protease inhibitor cocktail (Roche) for 1 h at 4°C. Cellular debris was removed by centrifugation at 13000 rpm for 15 min. Total protein concentration was determined by Bradford assay, and equal concentrations were separated by 10% SDS–PAGE and transferred to nitrocellulose membranes. Membranes were blocked in 6% non-fat dry milk and incubated with primary antibodies overnight at 4°C. Horse-radish peroxidase
(HRP)-conjugated secondary antibodies were incubated for 1 h at room temperature, and membranes were developed with enhanced chemiluminescence (Western lightening Plus-ECL, Perkin Elmer). Primary antibodies used were rabbit polyclonal anti-Tdp1 (1:500; MW: ~75 kDa) developed in the laboratory by Eurogentec using TDP1<sup>151-688</sup> as an antigen, mouse monoclonal anti-Top1 (1:1000; MW: ~100 kDa) from Santa Cruz biotechnology (sc-32736), rabbit polyclonal anti-APE1 (1:1000; MW: ~37 kDa) from Novus Biologicals (NB100–101), anti-Tubulin (1:3000; MW: ~55 kDa) from Abcam (ab4074), anti-MGMT (1:1000; MW: ~75 kDa) from Abcam (ab7045), anti-MyC (1:4000; 9B11; cell signalling), anti-PCNA (1:2000; MW: ~29 kDa) from Alan Lehmann and anti-Actin (1:3000; MW: ~42 kDa) from Sigma-Aldrich (a3853). HRP-conjugated secondary antibodies were from Dako (1:3000; P0260 and P0448).

Clonogenic survival and viability assays

Cells were plated in 10-cm dishes in duplicate and mock-treated with DMSO or with the indicated doses of camptothecin (CPT; Sigma) for 1 h, methyl methanesulfonate (MMS; Sigma) for 15 min, Temozolomide (TMZ; Sigma) at 37°C. Where indicated, cells were pre-incubated with 150 μM APE1 inhibitor CRT0044876 (Sigma) for 90 min (MRC5) or 120 min (cancer cell lines) or with 1 μM PARP inhibitor Olaparib for 60 min. Cells were washed 1× with phosphate-buffered saline and 2× with complete medium. Cells were then allowed to grow for 7–10 days until the formation of macroscopic colonies. Colonies were fixed in 80% cold ethanol and stained with 1% methylene blue. Survival was calculated by dividing the average number of colonies on treated plates by the average number of colonies on untreated plates. Data are the mean ± s.e.m. of three biological replicates.

DT40 cells (0.5 ml; 1 × 10<sup>5</sup> cells in 10 ml) were mixed with 0.5 ml media containing increasing concentrations of CPT or MMS in the presence or absence of 0.5 μM PARP inhibitor Olaparib. Five hundred cells/well were seeded in triplicate into 96-well plates with 100 μl of medium/well. Plates were incubated at 39°C for 72 h and cell viability determined using the CellTiter-Blue kit (Promega). Briefly, 20 μl of CellTiter-Blue reagent was added to each well and fluorescence was measured at 560 nm Ex/590 nm Em using GloMax®-Multi Detection System (Promega) and data analyzed using SigmaPlot. Viability of untreated cells was set to 100% and error bars represent standard error from three independent biological repeats.

Alkaline single-cell agarose gel electrophoresis assays

Cells were incubated with the indicated doses of CPT for 60 min or MMS for 15 min at 37°C. DNA strand breakage [primarily DNA single-strand breaks (SSBs) and alkali labile sites] were quantified by alkaline comet assays essentially as described (22). Briefly, cells were suspended in pre-chilled phosphate buffered saline (PBS) and mixed with equal volume of 1.2% low-gelling-temperature agarose (Sigma, Type VII) maintained at 42°C. Cell suspension was immediately layered onto pre-chilled frosted glass slides (Fisher) pre-coated with 0.6% agarose and maintained in the dark at 4°C until set, and for all further steps. Slides were immersed in pre-chilled lysis buffer [2.5 M NaCl, 10 mM Tris–HCl, 100 mM ethylenediaminetetraacetic acid (EDTA) (pH 8.0), 1% Triton X-100 and 1% dimethylsulfoxide (DMSO); (pH 10)] for 1 h, washed with pre-chilled distilled water (2 × 10 min) and placed for 45 min in pre-chilled alkaline electrophoresis buffer (50 mM NaOH, 1 mM EDTA and 1% DMSO). Electrophoresis was then conducted at 1 V/cm for 25 min, followed by neutralization in 400 mM Tris–HCl (pH 7.0) for 1 h. Finally, DNA was stained with Sybr Green I (1:10 000 in PBS) for 30 min. Average tail moments from 50 cells/sample were measured using Comet Assay IV software (Perceptive Instruments, UK). Data are the average ± s.e.m from three independent experiments. Statistical analyses were conducted using student t-test.

Measurement of global RNA transcription

MRC5 cells were grown on coverslips for 48–72 h in complete media deprived of serum. The Click-it RNA Alaxa Flour 488 Kit (Invitrogen) was used according to manufacturer’s instructions to quantify global RNA transcription. Briefly, cells were treated with the indicated doses of CPT for 1 h or with MMS for 15 min and either harvested immediately after treatment or washed twice with serum-free medium and incubated in drug-free medium for a subsequent 3 h to allow for transcription recovery. Cells were incubated with 0.1 mM 5-ethyl uridine (EU) for 30 min in presence or absence of CPT or MMS to label newly synthesized RNA. Cells were washed with PBS, fixed with 3.7% formaldehyde for 15 min and permeabilized with 0.5% Triton-X100 for 20 min at room temperature. Cells were then incubated with Click iT reaction cocktail containing Click-iT additive and Alexa Flour azide 488 for 30 min at 37°C. Following washing with PBS containing 3% BSA, cells were mounted on glass slides using a DAPI containing antifade medium. RNA labeled with EU was then subjected to immunofluorescence analyses. Average fluorescence signal was quantified from 200 to 300 cells using Corel Photo Draw software.

RESULTS

To examine the role of TDP1 in response to DNA alkylation damage, we generated human MRC5 cells in which endogenous level of TDP1 was stably depleted using shRNA. TDP1 expression in cells infected with TDP1 shRNA was reduced by ~90% compared with cells infected with control shRNA (Figure 1a). Consistent with a role for TDP1 in repairing Top1-mediated DNA damage, TDP1-depleted cells (TDP1<sup>KD</sup>) were more sensitive than controls to the Top1 poison camptothecin (CPT) (Figure 1b). To test whether TDP1 depletion confers hypersensitivity to base damage, we incubated control and TDP1<sup>KD</sup> cells with increasing concentrations of the alkylating agent methyl methanesulfonate (MMS). MMS
TDP1 promotes the repair of alkylation-induced base damage in human cells. (a) Human MRC5 cells were infected with lentivirus particles containing non-targeting control shRNA ‘WT’ or shRNA against human TDP1 ‘TDP1KD’. Cell lysates were fractionated by SDS-PAGE and analyzed by immunoblotting using anti-TDP1 (Eurogentec), anti-Top1 (Santa Cruz) or anti-actin (Sigma) immunoblotting. (b) WT or TDP1KD MRC5 cells were incubated with the indicated concentrations of camptothecin ‘CPT’ for 60 min at 37°C. (c) survival was determined in WT and TDP1KD MRC5 cells following exposure to the indicated doses of the alkylating agent methyl methanesulfonate (MMS) for 15 min at 37°C. Data are the mean ± s.e.m. of three biological replicates. Asterisks denote statistically significant difference between WT and TDP1KD (P = 0.04, 0.001, 0.02, 0.002 for MMS doses 0.1, 0.25, 0.5 and 0.75 µg/ml, respectively; t-test).

Figure 1. TDP1 promotes the repair of alkylation-induced base damage in human cells. (a) Human MRC5 cells were infected with lentivirus particles containing non-targeting control shRNA ‘WT’ or shRNA against human TDP1 ‘TDP1KD’. Cell lysates were fractionated by SDS-PAGE and analyzed by immunoblotting using anti-TDP1 (Eurogentec), anti-Top1 (Santa Cruz) or anti-actin (Sigma) immunoblotting. (b) WT or TDP1KD MRC5 cells were incubated with the indicated concentrations of camptothecin ‘CPT’ for 60 min at 37°C and the ability of single cells to form macroscopic colonies was determined by dividing the average number of colonies on untreated plates and predetermined by dividing the average number of colonies on treated and the ability of single cells to form macroscopic colonies was determined. Consistent with published data (23–25), depletion of ~90% of cellular APE1 (Figure 2a) led to ~10-fold reduction of the cellular resistance to MMS (Figure 2b). Notably, co-depletion of APE1 and TDP1 led to enhanced cell sensitization to MMS above that observed for depletion of TDP1 or APE1 alone, suggesting that TDP1 operates in a parallel pathway to APE1, to repair MMS-induced DNA damage. This was further confirmed by pharmacological inhibition of APE1 repair activity using CRT0044876 (26,27) (Figure 2c). These observations are consistent with cellular studies in S. pombe where tdp1 apn2 double mutant cells showed synergistic increase in MMS sensitivity compared with single mutants (16). To test whether the lyase (either AP, 3’-dRP or both) activity of TDP1 could explain, at least in part, the sensitivity of TDP1KD cells to MMS, we measured DNA strand breaks and abasic sites using alkaline single-cell gel electrophoresis (comet assays). We postulated that the monofunctional alkylating agent MMS would produce base alkylation, which would undergo spontaneous or glycosylase-mediated base release to generate cytotoxic abasic sites. The alkaline nature of the comet assay would uncover abasic sites resulting from defects in APE1 or TDP1. Similarly, processing of AP sites in cells and generation of 3’-dRP lesions would also result in detectable SSBs by the alkaline comet assay. As predicted, depletion of APE1 led to ~2.5-fold increase of SSBs (Figure 2d). Although depletion of TDP1 led to an increase of MMS-induced SSBs, co-depletion of TDP1 and APE1 led to higher number of SSBs than depletion of either enzyme alone.

It is worth noting that 3’-dRP lesions are more cytotoxic than AP sites, and thus more likely to account for the survival data (Figure 2b), as they would not be bypassed by translesion polymerases. We, therefore, hypothesized that overexpression of APE1 would generate excessive toxic intermediates that exceeds the ability of downstream repair factors to deal with, causing cellular hypersensitivity to MMS. If it is true that TDP1 protects from APE1-induced lesions, either directly or indirectly, then its overexpression would confer protection. To test this hypothesis, we generated MRC5 cells in which APE1 and TDP1 were ectopically overexpressed separately or together, and compared their sensitivity to MMS (Figure 3a). APE1 overexpression sensitized MRC5 cells to MMS, which is consistent with published work (28) and, importantly, increasing the cellular pool of TDP1 offered a remarkable protection (Figure 3b and Supplementary Figure S1). Together, these data demonstrate that TDP1 protects human cells from MMS damage.
How does TDP1 fulfill cellular protection from alkylation damage? DNA nicks and gaps have been shown to trap Top1 on DNA resulting in Top1 single-strand breaks (Top1-SSBs), and the ability of TDP1 to process these structures (29) may contribute to its protective role in response to MMS. To test whether this is the case, we generated human cells in which TDP1 and Top1 were depleted separately or together (Figure 4a). We first examined the accumulation of Top1-SSBs following exposure to CPT (Figure 4b). TDP1KD cells accumulated ~5-fold more Top1-SSBs than control cells while additional depletion of Top1 prevented their accumulation (Figure 4b). Furthermore, Top1 depletion protected TDP1KD cells from cell death induced by CPT to levels comparable with those observed in control cells (Figure 4c). We noted, however, that depletion of Top1 did not fully protect TDP1KD cells from CPT as it did for control cells. We reasoned this may be due to ~25% residual Top1 expression in Top1KD/TDP1KD double mutants compared with almost complete Top1 depletion in single Top1KD cells (Figure 4a). Additional depletion of Top1 using siRNA led to marked reduction of
Top1 expression (Figure 4d) and increased the CPT resistance of Top1 KD/TDP1 KD double mutants to levels observed in single Top1 KD cells (Figure 4e).

Having now established a cellular system to specifically study Top1-SSBs in response to genotoxic stress, we next examined their contribution to the cytotoxicity conferred by MMS. To our surprise, depletion of Top1 conferred remarkable protection in TDP1 KD cells from MMS damage (Figure 5a), suggesting that Top1-breaks contribute to MMS-induced cytotoxicity. If it is true that MMS induces Top1-breaks, then persistent exposure to MMS would result in Top1 degradation similar to persistent exposure to CPT. Incubation of MRC5 cells with CPT led to remarkable reduction of global transcription, which was restored to background levels following subsequent incubation in CPT-free media (Figure 6a). Consistent with a role for TDP1 to repair transcription-blocking Top1-breaks (21), its depletion led to a reduction in transcription that failed to recover during 2 h incubation in CPT-free media. Importantly, transcription decline in these experiments was owing to Top1-DNA breaks because Top1-depletion ablated the CPT-induced transcription decline.

We next examined transcription recovery following MMS. Similar to CPT, incubation of control cells with MMS reduced global transcription, which was restored to background levels following incubation in MMS-free media. Interestingly and consistent with a role for TDP1 in response to alkylation damage, TDP1-deficient cells failed to restore background transcription levels following MMS treatment of Top1-deficient cells (Top1 KD) also led to a comparable reduction in transcription to that observed in Top1 proficient cells, suggesting that MMS induces transcriptional arrest via a Top1-independent mechanism, presumably via the ability of AP sites and 3’dRP lesions to block progression of RNA polymerases. Consistent with this, additional depletion of TDP1 in Top1 KD cells led to a similar reduction in transcription, which was not restored to background levels during MMS-free recovery periods. We conclude from these experiments that TDP1 promotes transcription recovery.

Figure 3. Overexpression of TDP1 protects human cells from MMS-induced DNA damage. (a) MRC5 cells were transfected with an empty mammalian expression vector ‘Vector’, or constructs encoding Flag-APE1, Myc-TDP1 or both. Expression of fusion proteins was analyzed by fractionating cell lysates using SDS-PAGE and immunoblotting, using anti-TDP1 (Eurogentec), anti-APE1 (Novus) or anti-tubulin (Sigma) antibodies. (b) MRC5 ectopically expressing Flag-APE1, Myc-TDP1 or both was incubated with the indicated concentrations of MMS and percentage survival calculated from three independent replicates. Data are the mean ± s.e.m. Asterisks denote statistical difference (P < 0.01; t-test) between cells overexpressing APE1 alone and cells expressing both APE1 and TDP1.
following MMS and suggest that this is due to its AP/3’-dRP lyase activity.

To what extent do TDP1’s phosphodiesterase and lyase activities contribute to the protective effect from MMS? As both activities use the same active site (17), it was difficult to generate a separation-of-function mutant. We reasoned that eliminating the contribution of TDP1 phosphodiesterase activity on MMS-induced Top1-breaks by depleting Top1, coupled with limiting APE1 lyase function, would allow us to directly examine the lyase role of TDP1. Any sensitization induced by TDP1 knockdown in this system would be due to its lyase and not phosphodiesterase activity. Pharmacological inhibition of APE1 or its siRNA-mediated depletion sensitized Top1 KD cells to MMS (Figure 7a, b), reflecting the importance of APE1 lyase to protect from MMS. Importantly, additional depletion of TDP1 led to marked sensitization (compare open and closed circles...
observations in chicken DT40 cells where inhibition of Poly (ADP-ribose) polymerase (PARP) activity did not further sensitize Tdp1−/− cells to Top1 poisons (Figure 8a). Inhibition of PARP has been shown to impair DNA SSB repair due to trapping of the enzyme at repair intermediates, physically blocking subsequent repair events (30). We reasoned that if the cytotoxicity of TDP1-deficient cells to MMS is mediated solely via Top1-breaks then PARP inhibition would not confer additional sensitization, as is the case for Top1 poisons. In a remarkable contrast to this proposition, Tdp1−/− cells treated with the PARP inhibitor Olaparib were significantly more sensitive to MMS than untreated cells (Figure 8b). This was also confirmed in human MRC5 cells in which TDP1 levels were stably depleted using shRNA (Figure 8c). These data suggest that PARP and TDP1 operate together to repair Top1-breaks but independently to repair AP/dRP breaks (Figure 8d).

Finally, to examine whether the involvement of TDP1 in MMS damage could be applied to improve alkylation-based chemotherapy, we screened a panel of cancer cell lines for TDP1 expression. We identified RKO and DLD1 colorectal cancer cells that express remarkably different levels of TDP1 (Figure 9a, left) and then compared their ability to survive MMS damage. Consistent with our data, DLD1 cells were more sensitive than RKO to MMS (Figure 9a, right). This hypersensitivity was not due to different levels of APE1 or Top1 (Figure 9a) and was not due to the non-isogenic nature of the two cell lines, as depletion of TDP1 using siRNA in RKO also led to marked sensitization to MMS (Figure 9b). Alkylation-based chemotherapy such as Temozolomide (TMZ) are widely used to treat a variety of human cancers, most notably Glioblastoma Multiforme (GM), which is the most common aggressive adult primary tumor of the central nervous system. TMZ delivers a methyl group to purine bases of DNA, resulting in O6-methyl guanine, N7-methyl guanine and N3-methyl adenine. The primary cytotoxic lesion is believed to be O6-methyl guanine, which can be removed by a direct repair mechanism mediated by methylguanine methyltransferase (MGMT). Inherent and acquired resistance to TMZ via MGMT expression present major obstacles in the clinical management of GM. In light of the data presented above, we reasoned that reducing TDP1 levels might offer a new tool to sensitize TMZ-resistant GM cells to alkylation damage. Consistent with previous work (31), T98G GM cells expressing MGMT exhibited significantly higher levels of resistance to TMZ than U87 cells that express undetectable levels of MGMT (Figure 9c). Depletion of TDP1 or the additional depletion of APE1 led to marked sensitization of T98G cells to TMZ (Figure 9d), suggesting the importance of determining and/or manipulating TDP1 expression levels to improve the clinical outcome of TMZ-based chemotherapy.

**DISCUSSION**

Accumulating evidence suggest that human cells use distinct but functionally overlapping pathways to handle the endogenous and external load of DNA damage. As cancer...
Figure 6. TDP1 promotes transcription recovery following alkylation-induced DNA damage. (a) Control MRC5 cells ‘WT’ grown on coverslips were maintained for 2 days in serum-free media, treated with DMSO ‘Mock’ or with 20 µM CPT ‘CPT’ for 1 h and either harvested immediately after treatment or incubated in CPT-free media for a subsequent 3 h to allow for transcription recovery. Cells were incubated with 0.1 mM 5-ethynyl uridine (EU) for 30 min to label newly synthesized RNA, which was visualized by using the Click it reaction with Alexa Flour azide 488. EU-labeled RNA was subjected to immunofluorescence analyses and DNA counterstained with 4',6-diamidino-2-phenylindole (DAPI). Representative micrographs are depicted. (b) TDP1KD or Top1KD MRC5 cells were examined for nascent RNA synthesis as described in (a). (c) Average fluorescence signal (arbitrary units ‘AU’) from 200 to 300 cells as described in (a) and (b) were quantified from three biological replicates ± s.e.m. (d) The indicated MRC5 cells were grown in serum-free medium and treated with 2 µg/ml MMS for 15 min at 37°C. Cells were either harvested immediately after treatment ‘MMS’ or incubated in MMS-free media for a subsequent 1 h ‘R’. Newly synthesized RNA was quantified and average fluorescence signal of EU-labeled RNA was quantified as described earlier from three biological replicates.
cells are often perturbed in many DNA repair pathways (32), understanding the complexity of functional redundancy is key in exploiting the inherent biological variations in cancer. This study reveals a synergistic sensitivity of cells depleted for TDP1 and APE1 to alkylating agents, raising the possibility that TDP1 inhibitors could selectively target tumors with perturbed APE1 expression. In addition, the administration of alkylating agents in cancer cells in which TDP1 is inherently deficient, or in combination with TDP1 inhibitors, may also provide a new anti-cancer strategy to target specific class of tumors, particularly those that are resistant to alkylation damage such as temozolomide-resistant GM. In contrast to APE1 inhibition, TDP1 suppression is a more attractive tool, as it is predicted to provide a better tolerance during chemotherapy. This is suggested by gene knockout experiments in vertebrate systems where TDP1 deletion, unlike that of APE1, is not essential for organismal survival (33–35).

TDP1 was first identified as an activity in S. cerevisiae that is capable of cleaving the covalent phosphodiester linkage between a tyrosine residue in Top1 and 3’-phosphate on DNA (36). This type of DNA linkage is
... activity has been reported for human and S. pombe TDP1, where, in the latter, it presents the major APE1-independent activity. It is likely that TDP1 AP/dRP lyase is more important in yeast than in human due to the lack of NEIL proteins in yeast, which provide an extra layer of redundancy in dealing with AP sites in human cells (40). However, experiments in DT40 cells (15) and our...
DLD1
N7 methyl
for 15 min at 37
DMSO or 150
guanine, N7-methyl guanine and N3-methyl adenine. The primary cytotoxic lesion is believed to be O6-methyl guanine, which can be removed by a
exposure to the indicated doses of MMS, as described earlier in the text (right). MMS (right).
were compared with low-MGMT expressing U87 cells for their survival following exposure to increasing concentrations of the alkylating agent
analyzed for methylguanine methyltransferase (MGMT) expression using anti-MGMT antibodies (Abcam) (left). High-MGMT expressing T98G cells
immunoblotting (left). Control T98G cells (T98GSc siRNA) and cells in which TDP1 levels were depleted (TG98TDP1 siRNA) were incubated with
outcome of temozolomide-based cancer therapy. Asterisks denote statistical differences (P < 0.05; t-test) between control and TDP1-deficient cells.

Figure 9. TDP1 depletion sensitizes glioblastoma-resistant cancer cells to temozolomide. (a) Cell lysates from RKO and DLD1 cancer cell lines were
fractionated by SDS-PAGE and analyzed by immunoblotting using anti-TDP1 (Eurogentec), anti-Top1 (Santa Cruz), anti-Tubulin (Abcam) and
anti-APE1 (Novus) antibodies (left). RKO and DLD1 cells were compared for their survival following exposure with the indicated doses of MMS for
15 min at 37°C (right). Data are the average of three independent experiments ± s.e.m. Where not visible, error bars are smaller than the symbol.
(b) RKO cells were subjected to scrambled siRNA (Mock) or siRNA against TDP1 (TDP1KD) and cell lysates analyzed by immunoblotting (left).
Control RKO (RKOsc siRNA) and RKO cells in which TDP1 levels were depleted (RKO TDP1 siRNA) were examined for their survival following exposure to the indicated doses of MMS for
15 min at 37°C (right). Data are the average of three independent experiments ± s.e.m. Where not visible, error bars are smaller than the symbol.
(c) Glioblastoma multiforme T98G and U87 cancer cell lines were analyzed for methylguanine methyltransferase (MGMT) expression using anti-MGMT antibodies (Abcam) (left). High-MGMT expressing T98G cells
were compared with low-MGMT expressing U87 cells for their survival following exposure to increasing concentrations of the alkylating agent
temozolomide (right). (d) T98G cells were subjected to scrambled siRNA (Mock) or siRNA against TDP1 (TDP1KD) and cell lysates analyzed by
immunoblotting (left). Control T98G cells (T98Gsc siRNA) and cells in which TDP1 levels were depleted (T98GTDP1 siRNA) were incubated with
DMSO or 150 μM of the APE1 inhibitor CRT0044876 ‘APEi’ for 2 h followed by additional incubation with the indicated concentrations of MMS
for 15 min at 37°C. Cell survival was blindly scored from three independent biological repeats, and data are the average ± s.e.m. (right). (e) Model
for the repair of temozolomide-induced DNA breaks. Temozolomide delivers a methyl group to purine bases of DNA, resulting in O6-methyl
guanine, N7-methyl guanine and N3-methyl adenine. The primary cytotoxic lesion is believed to be O6-methyl guanine, which can be removed by a
direct repair mechanism mediated by methylguanine methyltransferase (MGMT). Inherent and acquired resistance to temozolomide via MGMT
expression presents a major challenge in cancer therapy, particularly for glioblastoma multiforme. TDP1 promotes the repair of methylated purines
induced by temozolomide via a distinct non-canonical BER pathway. Increasing the load of unrepaired methylated purines by exploiting the limited
availability of TDP1 alone or in combination with canonical BER factors such as APE1 provides a new synthetic lethal setting to improve the clinical
outcome of temozolomide-based cancer therapy. Asterisks denote statistical differences (P < 0.05; t-test) between control and TDP1-deficient cells.
observations here, showing a protective role of TDP1 independently of Top1 suggest a role for its lyase activity in human cells. Thus, despite its weaker activity on AP/dRP compared with canonical 3'-phosphotyrosyl substrates (15), we suggest that TDP1 AP/dRP lyase has a role in human cells, particularly if APE1 is limiting.

In addition to their use in the clinic to kill cancer cells, alkylation damage is almost unavoidable and it is intriguing to speculate that the progressive accumulation of AP/3'-dRP lesions may also contribute to neurological decline observed in TDP1-deficient patients with spinocerebellar ataxia with axonal neuropathy (SCAN1) (41). Accumulation of Top1-breaks during transcription has been associated with the neurological decline in SCAN1 and in other cerebellar degenerative hereditary disorders such as ataxia telangiectasia (42). However, the Top1-independent nature of transcriptional decline observed here (Figure 6d) suggests that the role of TDP1 during transcription in response to base damage is likely due to its lyase rather than its tyrosyl DNA phosphodiesterase activity.

One of the important observations of the current study is the demonstration that Top1 depletion protects mammalian cells from alkylation damage. Biochemical analyses have shown that Top1 can be trapped by a variety of endogenous DNA lesions including AP sites and strand breaks (43,44). Lethal DNA double-strand breaks (DSBs) can be generated by replication runoff of Top1-SSBs during S-phase, which likely contributes to the cell killing observed in this study following MMS. It is thus possible that in addition to its 3'-dRP/AP lyase (16,45) human TDP1 can protect from base damage via its ability to disjoin Top1 peptides from DNA. Intriguingly, the former activity appears to be PARP independent, as PARP inhibition further sensitized TDP1-deficient cells to MMS, whereas it did not for CPT. It is likely that PARP and TDP1 function together in the same pathway to limit DSB formation and replication runoff following Top1 poisoning (46). We propose a model where PARP activity coordinates fork stabilization with the removal of stalled Top1 peptide from DNA termini by TDP1. This dual action of PARP may provide sufficient time to repair Top1-breaks by slowing or reversing the forks while promoting the resolution of Top1-breaks and preventing DSB formation. On the other hand, PARP inhibitors may trap PARP on a subset of MMS-induced repair intermediates, uncoupling them from subsequent repair and generating toxic lesions at replication forks that are distinct from those processed by TDP1 (47), thereby causing synergistic lethality. It is possible that the latter breaks are sufficiently different in origin, structure or accessibility to repair than those processed by PARP-related mechanisms and that enzymes acting on them are somehow excluded from acting on the other distinct class of breaks. Much remains to be determined on how these two pathways are prioritized in cells and whether one pathway predominates under particular circumstances. Nevertheless, these observations provide a new mechanistic rationale for the synergy of combining PARP inhibitors and Top1 poisons in clinical trials (46,48) and suggest the limited clinical utility of TDP1 in this context but highlights its potential importance during PARP inhibitor and TMZ combined therapy.

In summary, these data demonstrate a role for TDP1 in response to alkylation damage in human cells and illustrates the potential application of this knowledge to improve alkylation-based cancer therapy. TDP1 promotes the repair of both Top1- and AP/3'-dRP breaks induced by alkylating agents via its tyrosyl DNA phosphodiesterase and AP/3'dRP lyase activities. Although the former is PARP dependent the latter is PARP independent, opening new treatment paradigms for the emerging clinical applications of PARP inhibitors.

SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

ACKNOWLEDGEMENTS

We wish to thank Shih-Chieh Chiang for technical help, Dr Alan Lehmann for anti-PCNA antibodies, Dr Grigory Dianov and Dr Conelia Meisenberg for Flag-APE1 expression construct, Dr Anthony Chalmers for useful discussions, Dr Duncan Gilbert for RKO and DLD1 cell lines and Dr Mariella Mannino for Olaparib.

FUNDING

This work is funded by a Wellcome Trust fellowship [085284] and grant [091043 to S.E.-K.] whose lab is supported by a Lister Institute of Preventative Medicine Fellowship. Funding for open access charge: Wellcome Trust.

Conflict of interest statement. None declared.

REFERENCES

1. Lindahl,T. and Nyberg,B. (1972) Rate of depurination of native deoxyribonucleic acid. Biochemistry, 11, 3610-3618.
2. Rydberg,B. and Lindahl,T. (1982) Nonenzymatic methylation of DNA by the intracellular methyl group donor S-adenosyl-L-methionine is a potentially mutagenic reaction. EMBO J., 1, 211-216.
3. Hecht,S.S. (1999) DNA adduct formation from tobacco-specific N-nitrosamines. Mutat. Res., 424, 127-142.
4. Kato,S., Bowman,E.D., Harrington,A.M., Blomeke,B. and Shields,P.G. (1995) Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J. Natl Cancer Inst., 87, 902-907.
5. Lindahl,T. (1993) Instability and decay of the primary structure of DNA. Nature, 362, 709-715.
6. Dalhus,B., Laerdahl,J.K., Bakke,P.H. and Bjorås,M. (2009) DNA base repair—recognition and initiation of catalysis. FEMS Microbiol. Rev., 33, 1044-1078.
7. Ciccia,A. and Elledge,S.J. (2010) The DNA damage response: making it safe to play with knives. Mol. Cell, 40, 179-204.
8. Loeb,L.A. and Preston,B.D. (1986) Mutagenesis by apurinic/apyrimidinic sites. Annu. Rev. Genet., 20, 201-230.
9. Demple,B. and Sung,J.S. (2005) Molecular and biological roles of Ape1 protein in mammalian base excision repair. DNA Repair (Amst.), 4, 1442-1449.
10. Caldecott,K.W. (2008) Single-strand break repair and genetic disease. Nat. Rev. Genet., 9, 619-631.
25. Wilson, D.M. and Simeonov, A. (2010) Small molecule inhibitors of DNA base excision repair. *Nucleic Acids Res.*, 38, 4937–4947.

26. Mohammed, M.Z., Vyjayanti, V.N., Laughton, C.A., Dekker, L.V., Rognes, T., Bjørasta˚s, M. and Alseth, I. (2012) AP endonuclease independent repair of abasic sites in Schizosaccharomyces pombe. *Nucleic Acids Res.*, 40, 2000–2009.

27. Lebedeva, N.A., Rechkunova, N.I., El-Khamisy, S.F. and Lavrik, O.I. (2012) Tyrosyl-DNA phosphodiesterase 1 initiates repair of apurinic/apyrimidinic sites. *Biochimie*, 94, 1749–1753.

28. Boyd, D., Florent, G., Kim, P. and Brattain, M. (1988) Determination of the levels of urokinase and its receptor in human colorectal carcinoma cells. *Cancer Res.*, 48, 3112–3116.

29. Chen, T.R., Hay, R.J. and Macy, M.L. (1983) Intercellular karyotypic similarity in near-diploid cell lines of human tumor origins. *Cancer Genet. Cytogenet.*, 10, 351–362.

30. Zeng, Z., Sharma, A., Ju, L., Murai, J., Umsan, L., Vermeiren, L., Pommier, Y., Takeda, S., Huylebroeck, D., Caldecott, K.W. et al. (2012) TDPR2 promotes repair of topoisomerase I-mediated DNA damage in the absence of TDPR1. *Nucleic Acids Res.*, 40, 8371–8380.

31. Hudson, J.J.R., Chiang, S.C., Wells, O.S., Rookyard, C. and El-Khamisy, S.F. (2012) SUMO modification of the neuroprotective protein TDPR1 facilitates chromosomal single-strand break repair. *Nat. Commun.*, 3, 733–737.

32. Brassin, C., Clements, P.M., El-Khamisy, S.F., Petermann, E., Iles, N. and Caldecott, K.W. (2006) Measurement of chromosomal DNA single-strand breaks and replication fork progression rates. *Methods Enzymol.*, 409, 410–425.

33. Liu, L., Taverna, P., Whitacre, C.M., Chatterjee, S. and Gerson, S.L. (1999) Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. *Clin. Cancer Res.*, 5, 2908–2917.

34. Luo, M. and Kelley, M.R. (2004) Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. *Anticancer Res.*, 24, 2127–2134.

35. Wilson, D.M. and Simeonov, A. (2010) Small molecule inhibitors of DNA repair nucleic acids of APE1. *Cell Mol. Life Sci.*, 67, 3621–3637.

36. Mohammed, M.Z., Vyjayanti, V.N., Laughton, C.A., Dekker, L.V., Fischer, P.M., Wilson, D.M., Abbotts, R., Shah, S., Patell, P.M., Hickson, I.D. et al. (2011) Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines. *Br. J. Cancer*, 104, 653–663.

37. Madhusudan, S., Smart, F., Shrimpton, P., Parsons, J.L., Gardiner, L., Houbrook, S., Talbot, D.C., Hammond, T., Freemont, P.A., Sternberg, M.J.E. et al. (2005) Isolation of a small molecule inhibitor of DNA base excision repair. *Nucleic Acids Res.*, 33, 4711–4724.

38. Meisenberg, C., Tait, P.S., Diana, I., Wright, K., Edelmann, M.J., Ternette, N., Tasaki, T., Kessler, B.M., Parsons, J.L., Tae Kwon, Y. et al. (2012) Ubiquitin ligase UBR3 regulates cellular levels of the essential DNA repair protein APE1 and is required for genome stability. *Nucleic Acids Res.*, 40, 701–711.

29. Chiang, S.C., Carroll, J. and El-Khamisy, S.F. (2010) TDPR1 serine 81 promotes interaction with DNA ligase IIIalpha and facilitates cell survival following DNA damage. *Cell Cycle*, 9, 588–595.

30. Godon, C., Cordelier, F.P., Biard, D., Giocanti, N., Mégén-Chanet, F., HallJ. and Favaudon, V. (2008) PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility. *Nucleic Acids Res.*, 36, 4454–4464.

31. Dungey, F.A., Caldecott, K.W. and Chalmers, A.J. (2009) Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. *Mol. Cancer Ther.*, 8, 2243–2254.

32. Sultanwa, R., McNeill, D.R., Abbotts, R., Mohammed, M.Z., Zdzienicka, M.Z., Qutob, H., Seehouse, C., Laughton, C.A., Fischer, P.M., Patell, P.M. et al. (2012) Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. *Int. J. Cancer*, 131, 2433–2444.

33. El-Khamisy, S.F., Saifi, G.M., Weinfield, M., Johansson, F., Helleday, T., Lupschi, J.R. and Caldecott, K.W. (2005) Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. *Nature*, 434, 108–113.

34. Xanthoudakis, S., Smeaye, R.J., Wallace, J.D. and Curran, T. (1996) The redox/DNA repair protein, Ref-1, is essential for early embryonic development in mice. *Proc. Natl Acad. Sci. USA*, 93, 8919–8923.

35. Katyal, S., El-Khamisy, S.F., Russell, H.R., Li, Y., Ju, L., Caldecott, K.W. and McKinnon, P.J. (2007) TDPR1 facilitates chromosomal single-strand break repair in neurons and is neuroprotective in vivo. *EMBO J.*, 26, 4720–4731.

36. Yang, S.W., Burgin, A.B., Huizenga, B.N., Robertson, C.A., Yao, K.C. and Nash, H.A. (1996) A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerase. *Proc. Natl Acad. Sci. USA*, 93, 11534–11539.

37. Interthal, H., Chen, H.J., Kehl-FiE.T.E., Zottmann, J., Leppard, J.B. and Champoux, J.J. (2005) SCAN1 mutant TDPR1 accumulates the enzyme-DNA intermediate and causes camptothecin hypersensitivity. *EMBO J.*, 24, 2224–2233.

38. Zhou, T., Lee, J.W., Tatavarthi, H., Lupschi, J.R., Valerio, K. and Povirk, L.F. (2005) Deficiency in 3-phosphoglycerate processing in human cells with a hereditary mutation in tyrosyl-DNA phosphodiesterase (TDPR1). *Nucleic Acids Res.*, 33, 289–297.

39. Interthal, H., Chen, H.J. and Champoux, J.J. (2005) Human TDPR1 cleaves a broad spectrum of substrates, including phosphoamide linkages. *J. Biol. Chem.*, 280, 36518–36528.

40. Das, A., Wiederhold, L., Leppard, J.B., Kedar, P., Prasad, R., Wang, H., Boldogh, I., Karimi-Busheri, F., Weinfield, M., Wilk, D. and Topkumon, A.E. et al. (2006) NEIL2-initiated, APE1-dependent repair of oxidized bases in DNA: Evidence for a repair complex in human cells. *DNA Repair (Amst.)*, 5, 1439–1448.

41. Takashima, H., Boerkoel, C.F., John, J., Saifi, G.M., Salihi, M.A.M., Armstrong, D., Mao, Y., Quiocho, F.A., Rou, B.B., Nakagawa, M. et al. (2002) Mutation of TDPR1, encoding a topoisomerase I–dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. *Nat. Genet.*, 32, 267–272.

42. Alagoz, M., Chiang, S.C., Sharma, A. and El-Khamisy, S.F. (2013) ATM deficiency results in accumulation of DNA-Topoisomerase I covalent intermediates in neural cells. *Mol. Cancer*, 12, 4720–4731.

43. Pourquier, P., Ueng, L.M., Fertala, J., Wang, D., Park, H.J., Essmann, J.M., Borrsini, M.A. and Pommier, Y. (1999) Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8-oxoguanine and 5-hydroxyecytosine. *J. Biol. Chem.*, 274, 8516–8523.

44. Pommier, Y. (2006) Topoisomerase I inhibitors: camptothecins and beyond. *Nat. Rev. Cancer*, 6, 789–802.

45. Muri, J., Huang, S.Y.N., Das, B.B., Renaud, A., Zhang, Y., Doroshow, J.H., Fij, J., Takeda, S. and Pommier, Y. (2012) Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. *Cancer Res.*, 72, 5588–5599.

46. Ray Chaudhuri, A., Hashimoto, Y., Herrador, R., Neelsen, K.J., Fachinetti, D., Bermejo, R., Coito, A., Costanzo, V. and Lopes, M. (2012) Topoisomerase I poisoning results in PARP-mediated replication fork reversal. *Nat. Struct. Mol. Biol.*, 19, 417–429.
47. Strom, C. E., Johansson, F., Uhlen, M., Szigyarto, C. A., Erixon, K., and Helleday, T. (2011) Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. *Nucleic Acids Res.*, **39**, 3166–3175.

48. Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J. *et al.* (2011) Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. *Cancer Res.*, **71**, 5626–5634.